Oslo Cancer Cluster member Photocure recently announced that the U.S. Food and Drug Administration (FDA) has accepted an expansion of the bladder cancer detection system “Cysview”. The FDA has accepted a supplemental New Drug Application (NDA) for “Cysview”. Photocure, the Norwegian company behind the drug-device system, has now been allowed to expand the system to […]
Author Archive for: oslocancer
This author has yet to write their bio.Meanwhile lets just say that we are proud oslocancer contributed a whooping 314 entries.
Entries by oslocancer
Entering 2018, Oslo Cancer Cluster welcomes four new members to the fold. Cellmover, Bryn Aarflot, Kuehne + Nagel and Mercuri Urval are our new cluster members. The Importance of Getting There Founded in 1890, Kuehne + Nagel operates from 9 locations in Norway, offering tailored logistics solutions for different industries, including for healthcare and […]
Inven2 are distributing start-up funds in Life Science! Very good news for Biotechs and cancer research companies in their early stages of development. Attention all Oslo Cancer Cluster and Incubator members. Inven2 received in late December 5 million NOK from Innovation Norway. They are now, subsequently, handing them out to Life science start-ups. Inven2 […]
For the tenth time the cancer experts gathered to share knowledge and ideas at Oslo Cancer Cluster Innovation Park. Cancer Crosslinks 2018 presented a diverse program covering themes from immuno-oncology to cachexia, to big data. Cancer research is changing rapidly. Immunotherapy and precision medicine has revolutionized cancer treatment. This year’s Cancer Crosslinks took a […]
Thursday January the 18th it’s time for the 10th Cancer Crosslinks here at Oslo Cancer Cluster Innovation Park. Hospital personnel, researchers and everybody interested get together for an update on – and to discuss – the latest within cancer research. This year’s conference will focus on Precision Treatment in cancer research with the headline: […]
To secure Norwegian pharmaceutical production, Oslo Cancer Cluster- member Curida has completed a takeover of Ås produksjonslab AS. Continued Production at Ås Curida operate in an international marketplace and here the last line of production of pharmaceuticals is mostly taken care of by specialized operators. «Ås produksjonslab» is a company rich in tradition, it […]
Les kronikken, fra 21.12. 2017 i Aftenposten, om hvordan vi bør forme våre nye sykehusbygg av Ketil Widerberg. Den nye klinikken på Radiumhospitalet må ta helsedatarevolusjonen på alvor. Radiumhospitalet ved Oslo universitetssykehus får nytt klinikkbygg. En god nyhet for kreftpasienter, som blir enda bedre hvis pasientene selv får bidra med data om egen helse. Et […]
A new exciting collaboration among two Oslo Cancer Cluster members has been initiated. GE Healthcare has agreed to be the manufacturer of the target drug delivery platform ACT, made by Phoenix Solutions. Early Christmas Present As an early Christmas present to each other the two companies announced that they had signed an agreement securing manufacturing […]
The cancer research company and Oslo Cancer Cluster-member Oncoinvent opened this Thursday a brand-new lab and research facilities at Nydalen Oslo. Now they control the whole production line and continue their development of their lead product candidate Radspherin. A Good Year 2017 has been a good year for Oncoinvent. The company has now relocated and […]
Nacamed, Phoenix Soulutions, NorGenoTech and Clever Health are awarded Innovasjonsrammen for good early-stage innovation and collaboration. Innovasjonsrammen is awarded by Oslo Cancer Cluster with money from Innovation Norway. Congratulations! Important with early financing Early financing while companies are establishing their business is often limited, but can be crucial to get important projects off the ground. […]
You have probably heard of Black Friday. Now introducing Giving Tuesday: A day all about giving rather than buying. Eight Norwegian YouTubers have chosen to crowdfund on behalf of The Norwegian Cancer Society as part of Giving Tuesday. Raising money for cancer research and cancer patient care. A week before the big day five of […]
Nordic Mentor Network for Entrepreneurship (NOME) will be an important piece of the puzzle if Norway is going to fulfill their ambitions set by the coming White Paper on the Healthcare Industry. If we are to make our bioindustry more competitive and take a leading European role within eHealth, we need to learn from the […]
Researchers at the Centre for Cancer Biomedicine, a Center of Excellence and a member of Oslo Cancer Cluster, have discovered an enzyme wreaking havoc inside cells that turns into tumors. For our body to work as normal, cells need to know which way is up. When cells lose track of their orientation, they can start […]
This week on Monday, Prostate Cancer Day, the Norwegian Cancer Society initiated their Blue-Ribbon Campaign to raise prostate cancer awareness. In line with the campaign, Oslo Cancer Cluster gives you the chance to update yourselves on prostate cancer research Thursday the 30th of November. The Blue-Ribbon campaign is initially a month’s focus on prostate […]
Investors are recognizing the huge potential of Oslo Cancer Cluster member Ultimovacs. They are currently investing an additional 125 million NOK in the cancer research company. Well known investors and Ultimovacs backers Stein Erik Hagen, Anders Wilhelmsen og Bjørn Rune Gjelsten are among financiers putting fresh money into the cancer research company, according to […]
Oslo Cancer Cluster member Photucure recently announced that the U.S. Food and Drug Administration (FDA) has accepted a Priority Review for an expansion of Cysview. The FDA has accepted a supplemental New Drug Application (NDA) for Cysview on a priority review basis. Photocure, the Oslo, Norway-based company that developed and is marketing the drug-device […]
I kursserien Kompetanseutvikling i realfag (KUR), spør vi denne gangen: Er det farlig med stråling? Hvordan påvirkes vi av trådløse nettverk? Hvordan behandler man kreft med ioniserende stråling? Stråling er en del av hverdagen vår på mange måter. Det elektromagnetiske spekteret er også en gjenganger i mange læreplaner, både grunnskolen og i videregående skole. Denne kurskvelden har […]
Targovax has received very positive results regarding the survival rate of patients with pancreas cancer.
Les kronikken om digital helse av Ketil Widerberg.
Curida has come a long way from defending their place at the Norwegian factory to setting their sights internationally.
Luckily, all our events are available for a rerun.
The innovation company of the year wants to encourage young talents.
A new Norwegian research collaboration helps uncover what treatments are the right fit for American cancer patients.
Stanford programme SPARK for startup companies is coming to Norway. What exactly is SPARK?
Photocure reveals promising results in bladder cancer through the use of Blue Light Cytoscopy alongside the drug Hexvix.
On the 15th of August, drug Kadycla (trastuzumab emtansin) is finally approved by the Beslutningsforum and ready to help hundreds with breast cancer in Norway. The drug, developed by company Roche, specifically targets patients with the variant HER2 positive breast cancer – a breast cancer that tests positive for human epidermal growth factor receptor 2, […]
We are proud to introduce Oslo Cancer Cluster’s new members so far in 2017. Part 2 of 2.
We are proud to introduce Oslo Cancer Cluster’s new members so far in 2017. Part 1 of 2.
The Research Council of Norway has given Thermo Fisher Scientific the prestigious Innovation Award.
Hva har persontilpasset medisin potensial til å være – og hva skal til for å oppnå resultater av forskning og klinisk bruk? Se vårt første åpne møte under Arendalsuka 2017.
Dr. Bora Sieng, from Arctic Pharma, advocates for the importance of chemistry and encourages pupils to pursue a career in the exciting field of chemistry.
What kind of work does it take to receive PERMIDES funding for innovative concepts and projects?
Learn how Project DoMore! aims to better cancer treatment through modernized thinking and technological solutions.
The Department of Cellular Therapy is great at transforming cancer research into new companies.
24 oncology innovators from 9 international hubs attended the 6th International Cancer Cluster Showcase in San Diego.
Oslo Cancer Cluster aims to enhance the visibility of oncology innovation made in Norway. Find out how we go about making this happen.
Meet our newest board members!
Doctors, researchers and audience gather at breakfast to learn about genetics, data and how working together will help beat cancer.
A driving force behind the collaboration between Ullern Upper Secondary School and Oslo Cancer Cluster is stepping down. This is her adventure.
The cluster-to-cluster project PERMIDES stimulates collaboration between biotech companies and IT companies. Join the workshop in Oslo 24 May.
Oslo Cancer Cluster Incubator stakk av med Siva-prisen for 2017 på årets Siva-konferanse i Trondheim.
Thermo Fisher Scientific is one of three finalists to win the award and title in Oslo this Tuesday. The technology which the biotech company is nominated for, is development of faster and cheaper DNA-sequencing. More than 70 companies were candidates for this year’s price, according to the Norwegian online tech magazine Teknisk Ukeblad. Thermo Fisher Scientific is one […]
En ny rapport om helsenæringens verdi er ute. Du kan laste ned rapporten her.
Oslo Cancer Cluster member Roche has received approval by the Norwegian Medicines Agency for a medication against a specific form for lung cancer.
Join six pupils from Ullern Upper Secondary School to see how physics plays a crucial role in good cancer treatment.
The bioinformatics company OncoImmunity AS was ranked fourth out of 250 applicants for this prestigious grant.
Oslo Cancer Cluster member Vaccibody is moving forward with the first vaccination of a patient with the HPV-virus in a IIa study using the company´s immunotherapy.
Why join the PERMIDES platform? It is where you can find your biopharma-IT match.
Åtte elever fra Ullern videregående skole har denne uken vært på utplassering hos avdeling for patologi ved Oslo universitetssykehus. Morsomt har det vært, og Marie Wahlstrøm kan godt tenke seg å bli patolog.
Targovax ASA’s shares have been accepted to list on Oslo Børs, the main Oslo Stock Exchange. Targovax is a clinical stage company, developing immuno-oncology therapies to target treatment-resistant solid tumors.
The first call for proposals for the PERMIDES project is opening on March 15th. We urge all small and medium sized biopharma-companies working to take the step into the digital era: Apply for funding up to 60 000 Euros.
Nordic Mentor Network for Entrepreneurship (NOME) is an elite Nordic mentoring program for promising life science projects and startups with world class mentors.
Oslo Cancer Cluster member BerGenBio enters collaboration with MSD focused on clinical evaluation of BGB324 in combination with KEYTRUDA® (pembrolizumab) in advanced lung and breast cancer.
We are currently looking for an EU advisor with skills and experience in writing EU funding proposals. This is a fixed term contract with duration to the end of 2018.
IRW Consulting, Eisai and Personalis, Inc. are all new members of the Oslo Cancer Cluster. Please read more about them here.
De nordiske landene bør samarbeide mer for å utvikle bedre kreftbehandlinger. Sammen kan Norden bli et globalt forsknings- og testsenter for nye kreftbehandlinger og -medisiner. Det kan gi store gevinster for kreftpasienter i hele verden. Denne kronikken sto på trykk i Aftenposten torsdag 9. mars. Ketil Widerberg, daglig leder i Oslo Cancer Cluster, skrev kronikken samme uke som The Economist, Forskningsrådet og […]
Oslo, Norway, 6 March 2017: Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target, primarily, treatment-resistant solid tumors, announces that members of its senior management will present at the following life sciences and investor conferences:
– 10th European Life Science CEO Forum
– Redeye – Fight Cancer Seminar
– 11th Annual BIO-Equity Spring 2017 Conference
Oslo Cancer Cluster has a new Head of Communications. She wants to help you reach out.
Oslo Cancer Cluster member Radium Hospital Research Foundation, Radforsk, has launched their own podcast. The podcast is named Radium, and is about cancer research and development of new cancer treatments, as well as updates on Radforsk´s portfolio companies.
Oslo, Norway, 16 February 2017 – Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces its fourth quarter and full year 2016 results.
A meeting for investors, analysts and press will take place in Oslo today at 10:00 CET and a conference call will take place at 14.00 CET (details below).
Are you a startup or entrepreneur in Healthcare or Life-Sciences? If yes – keep reading!
Oslo Cancer Cluster member Photocure ASA reported that full year 2016 revenues ended at NOK 143.6 million (134.7). Photocure targets revenues from the US operations to quadruple to a range of USD 15 million by 2020.
Cancer Crosslinks is now one of the most relevant meetings for Norwegian oncologists, with 300 delegates attending this year. You may download the presentations here.
Oslo Cancer Cluster is proud to be partner of the Economist Events War On Cancer Nordics. The event will gather leaders in oncology from the Nordic region and beyond, to discuss the region’s primary challenges in cancer care and control.
Our portfolio company Oncoinvent announced today the closing of a 210 MNOK (approx. 25 MUSD) private placement of ordinary shares. Financing will support development of Radspherin™, a novel radiotherapeutic treatment for peritoneal carcinomatosis.
The Norwegian Research Council recently granted funding to Oslo Cancer Cluster members; BerGen Bio, Bionor Immuno, GE Healthcare, Lytix Biopharma, PCI Biotech and Phoenix Solutions.
Oslo Cancer Cluster member Targovax will announce its fourth quarter and full year 2016 results on Thursday, 16 February 2017.
Lytix Biopharma, a clinical-stage biopharmaceutical company developing novel cancer immune therapies, has been awarded a NOK 15.9 million grant from The Norwegian Research Council (User-driven Research-based Innovation) to support the investigation of LTX-315’s ability to make ’’cold tumors hot’’ and Phase II trial in Triple Negative Breast cancer (TNBC).
Survival rate of 68% from first patient cohort vs published historical rate of 30-53% suggests signal of clinical efficacy for the drug candidate. Full data set from first patient cohort to be submitted for presentation at ASCO annual meeting in June.
Oslo Cancer Cluster member Lytix Biopharma has been awarded a NOK 15.9 million grant from The Norwegian Research Council.
Our member PCI Biotech has been granted NOK 13.8 million to the project “Photochemical vaccination – novel immunotherapy concept for treatment of cancer and infectious diseases”.
Cancer Crosslinks 2017 on January 26 features a really interesting program with International and Norwegian thought leaders presenting recent findings within cancer research.
PCI Biotech, Ultimovacs, Arctic Pharma, Oncoimmunity and Myhere have been granted funding to develop improved cancer treatments through collaborative projects.
Dehns Patent and Trade Mark Attorneys recently joined the Oslo Cancer Cluster. Dehns is one of Europe’s largest firms of patent and trade mark attorneys and has a 40 year history of working with Norwegian organisations such as: Dynal, Inven2,Lytix Biopharma, Nextera, NMBU, NTNU, Nycomed, PCI Biotech and Photocure. As members, our aim is to […]
The PCI Biotech and Ultimovacs collaboration awarded NOK 500,000 from Innovation Norway
The immune oncology company Lytix Biopharma AS has enrolled the first patient in the Phase 1 study of LTX-315 in combination with immune checkpoint inhibitors (ICIs). Since LTX-315 turns immunogenically “cold” tumours “hot” it may be an ideal combination with other immunotherapies.
The Board of Directors of Phoenix Solutions is pleased to announce that the company has completed a series A financing led by a small group of healthcare angel investors.
Prime Minister Erna Solberg stated in her speech that Oslo Cancer Cluster´s financing in the future is secured by the Research Council.
Anne Lise Ryel, General Secretary of the Norwegian Cancer Society gave a powerful speech at the celebration of Oslo Cancer Cluster´s 10 years anniversary. Here she stresses the importance of collaboration and ensures the continued support to the cluster.
Oslo Cancer Cluster member Vaccibody succesfully raised NOK 220 million (€ 24 million). The Private Placement was significantly oversubscribed by both existing shareholders and new investors.
Nordic Nanovector has raised MNOK 500 in gross proceeds through a private placement of 4,374,244 new shares.
Gjennom det skolefaglige samarbeidet mellom Oslo Cancer Cluster og Ullern videregående skole har realfagselever hatt en ukes utplassering på avdeling for tumorbiologi ved Institutt for Kreftforskning ved Oslo universitetssykehus i syv år.
Nordic Nanovector presented the updated results from its ongoing Lymrit 37-01 Phase 1/2 clinical trial of Betalutin® (177Lu-satetraxetan-lilotomab) in subjects with relapsed non-Hodgkin lymphoma (NHL) at the 58th Annual American Society of Hematology (ASH) meeting (San Diego, CA, USA).
Photocure ASA (OSE:PHO) announced today that new 2016 French National Guidelines for the management of Bladder Cancer includes its Blue Light Cystoscopy (BLC) with Hexvix®.
Oslo Cancer Cluster member Photocure reported a revenue growth of 17 % to NOK 31.6 million in the third quarter of 2016 for the Hexvix/Cysview commercial franchise.
Cancer Crosslinks er den årlige møteplassen innen onkologi og hematologi, og det er med stor glede vi inviterer onkologer, hematologer og forskere til det niende Cancer Crosslinks i vår egen Oslo Cancer Cluster Innovasjonspark 26. januar 2017.
This composition of matter patent protects Targovax’s lead product from its ONCOS platform, the oncolytic viral product ONCOS-102 and expires in 2029. A US patent covering ONCOS-102 was granted in May 2016.
The biopharmaceutical industry is at a frenzy to develop innovative drugs for cancer. No wonder, when the market size is estimated to over 800 BNOK in 2020, the population world-wide is getting older and the incidence and prevalence of cancer is increasing.
Nordic Nanovector ASA will present the therapeutic effect of combined treatment with Betalutin® and rituximab in a preclinical model of non-Hodgkin lymphoma at the 58th Annual American Society of Hematology (ASH).
Oslo Cancer Cluster member PCI Biotech has initiated a process with the objective to carry out a share issue in the range of NOK 40-50 million by the end of November 2016.
NorGeno Tech & DNVGL are now members of the Oslo Cancer Cluster. Please find more information on the new members here.
Vi ønsker å komme i kontakt med medlemmer som har innspill til hvordan man kan legge til rette for enklere tilgang og bedre utnyttelse av helsedata.
Nordic Nanovector enters collaboration with Heidelberg Pharma GmbH to develop antobody drug conjugates for treating leukaemias.
RealKarriere is the Career Day for the The Faculty of Mathematics and Natural Sciences at University in Oslo. In 2017 the Career day will be arranged on February 9th 2017.
Kreftkostnader i Norge: Hvor ligger de største kostnadene? Hvilken kreftform er dyrest? Oslo Economics har utarbeidet en rapport om kostnadene ved kreft.
NCGC is joining forces with Norwegian Cancer Registry to establish a research platform for tumor-profiling in recruiting patients for clinical trials. They would like the help form members of the Oslo Cancer Cluster on what targets to include in the gene panel,
The Research Council is planning to announce up to NOK 45 million in funding for projects that promote value creation in the healthcare industry and is organising an applicant’s workshop on 24. October.
Nordic Nanovector ASA, is pleased to announce it has entered into a collaboration with LegoChem Biosciences, Inc. , a South Korea-based biopharmaceutical company, to develop novel CD37-targeting antibody-drug conjugates (ADCs) for the treatment of leukaemias.
December 15th is the date for the annual DNB HealthCare Conference. Be sure to apply for both the Health Care prize and to be a part of the Venture Session.
Over 50 people turned up for our R&D Network meeting on Precision Cancer Medicin at Stavanger University Hospital yesterday. The meeting was a collaboration beetween Oslo Cancer Cluster and Stavanger University Hospital(SUS) and was hosted by SUS.
Contact Team >
Oslo Cancer Cluster is an oncology research and industry cluster dedicated to improving the lives of cancer patients by accelerating the development of new cancer diagnostics and medicines.
We are a national non-profit member organization with about 90 members. Our members are Norwegian and international companies, research and financial institutions, university hospitals and organizations – all working in the cancer field.